Business Wire

NY-IWBI

8.6.2020 17:03:03 CEST | Business Wire | Press release

Share
International WELL Building Institute Launches WELL Health-Safety Rating for all Building and Facility Types

The International WELL Building Institute (IWBI) announced today the launch of the WELL Health-Safety Rating for all building and facility types, an evidence-based, third-party verified rating focusing on operational policies, maintenance protocols and design strategies to address a post COVID-19 environment. The WELL Health-Safety Rating is one of the earliest outcomes of IWBI’s Task Force on COVID-19 , a group of nearly 600 public health experts, virologists, government officials, academics, business leaders, architects, designers, building scientists and real estate professionals, which was established in late March to help guide IWBI’s response to the pandemic.

The WELL Health-Safety Rating provides a centralized source and governing body to validate efforts made by owners and operators. It leverages insights drawn from the IWBI COVID-19 Task Force, in addition to guidance on the spread of COVID-19 and other respiratory infections developed by the Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO), the Department of Health and Human Services pursuant to the Occupational Safety and Health Act (OSHA), the National Institutes of Health (NIH), and leading academic and research institutions, as well as core principles already established by IWBI’s WELL Building Standard. Participation in the program requires submission of policies, protocols and strategies for third-party document review and annual verification.

“The WELL Health-Safety Rating is a sign of confidence that measures have been enacted to help support the health and safety of people entering spaces of all kinds, and that those measures have been mapped to scientific evidence and verified through a third-party review process,” said Rick Fedrizzi, chairman & CEO of IWBI. “By drawing on the proven strategies in WELL, we’re working from the best science available and that’s more important than it’s ever been.”

The WELL Health-Safety Rating will accept registrations in June from all types of buildings and facility typologies, including offices, restaurants, hotels, retail establishments, manufacturing plants, warehouses, sports stadiums, arenas, theaters and other entertainment venues, schools, multi-family housing, and many others. Current WELL-registered projects and WELL Portfolio participants can earn the WELL Health-Safety Rating as part of their already established certification efforts.

“Our buildings and the people who tend them are our first line of defense for keeping us safe and healthy,” said Rachel Gutter, president of IWBI, “and the current pandemic has confirmed that health is a material economic consideration of the first order. These two simple truths stand at the nexus of our work to date and will, along with the hard evidence that is mounting, inform all our decisions about the critical need for better buildings, more vibrant communities and stronger organizations going forward.”

The WELL Health-Safety Rating is the first of many anticipated outcomes informed by the work of the IWBI COVID-19 Task Force that will be introduced in the coming months. Members of the Task Force include 17th Surgeon General of the United States Dr. Richard Carmona, former Robert Wood Johnson Foundation President and CEO Dr. Risa Lavizzo-Mourey, UCLA’s Dr. Jonathan Fielding, Harvard School of Public Health’s Joseph Allen, and environmental scientist Allen Hershkowitz Ph.D., among others.

“The Task Force has received overwhelming support and input from all over the world,” said Dr. Richard Carmona, 17th Surgeon General of the United States. “People are learning that buildings themselves can be powerful vehicles for protecting and improving public health. All of us individually have a responsibility to the collective whole to use every tool, including our buildings and our sense of community, to keep ourselves and those we care about safe.”

“The impacts of the virus have been many, but not the least is the anxiety of uncertainty about where people feel safe,” said Despina Katsikakis, Head of Occupier Business Performance at Cushman Wakefield and member of IWBI’s COVID-19 Task Force. “Achieving this new WELL Health-Safety Rating is a great way to increase confidence that evidence-based steps to do the right thing have been taken to keep health front and center as the economy reopens.”

Recently, IWBI released an interim Strategies from the WELL Building Standard to Support in the Fight Against COVID-19, another key outcome of the Task Force. Grounded in the foundation of WELL, these evidence-based strategies provide an actionable framework for organizations and communities as they advance a safer and healthier future. IWBI is expanding these strategies into Guidelines for Preparedness and Prevention, Resilience and Recovery in relation to COVID-19 and other respiratory infections. The Guidelines will provide insight into how the current strategies have evolved, as well as indicate areas where further work is required.

Since its inception, IWBI has been driving forward the convergence of building science and health science. Registrations under the WELL Building Standard, the premier standard for healthy real estate, have already surpassed 550 million square feet across 62 countries. The WELL Building movement has been further amplified by over 11,000 WELL Accredited Professionals (APs) and registrants across the globe.

Gutter noted that upon achieving the designation, IWBI will issue the project a WELL Health-Safety Rating seal. Register interest in the WELL Health-Safety Rating here .

About the International WELL Building Institute

The International WELL Building Institute (IWBI) is leading the global movement to transform our buildings, communities and organizations in ways that help people thrive. The WELL v2 pilot is the latest version of its popular WELL Building Standard (WELL), and the WELL Community Standard pilot is a district scale rating system that sets a new global benchmark for healthy communities. WELL is focused exclusively on the ways that buildings and communities, and everything in them, can improve our comfort, drive better choices, and generally enhance, not compromise, our health and wellness. IWBI mobilizes the wellness community through management of the WELL AP credential, the pursuit of applicable research, the development of educational resources, and advocacy for policies that promote health and wellness for everyone, everywhere. For more information about IWBI and WELL, visit us here .

International WELL Building Institute, IWBI, the WELL Building Standard, WELL v2, WELL Certified, WELL AP, WELL, WELL Portfolio, The WELL Conference, the WELL Community Standard, WELL Workforce, WELL Health-Safety Rating and others, and their related logos are trademarks or certification marks of International WELL Building Institute pbc in the United States and other countries.

Social Media:

https://facebook.com/wellbuildinginstitute/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye